Evidence map›Paper›PMID 41980923›Full record

ArticleTranslational psychiatry2026

Effects of a single dose of psilocybin on diet-induced weight loss in obese mice.

Ryan J Keenan, Rifa T Haque, Xiangjun Jin, Tomris Mustafa, Jihane Homman-Ludiye, Kayla Elysee, Zi Shan Wee, Stephanie E Simonds, Claire J Foldi, Michael A Cowley

Abstract read
In one paragraph

Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryan J KeenanDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.ORCID http://orcid.org/0000-0003-0768-0582
Rifa T HaqueDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Xiangjun JinDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Tomris MustafaDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Jihane Homman-LudiyeMonash Micro Imaging, Monash University, Clayton, Victoria, 3800, Australia.ORCID http://orcid.org/0000-0001-6689-1457
Kayla ElyseeDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Zi Shan WeeDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Stephanie E SimondsDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Claire J FoldiDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia. claire.foldi@monash.edu.ORCID http://orcid.org/0000-0002-3293-8242
Michael A CowleyDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia. michael.cowley@monash.edu.ORCID http://orcid.org/0000-0001-7811-134X

Funding

Department of Health | National Health and Medical Research Council (NHMRC) PURE ID: 284 997 536
6 · The paper itself

Abstract

Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese body weight. These circuits regulate various mechanisms which can inhibit extreme or persistent weight loss. Therefore, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticity within the brain. Psychedelic compounds, such as psilocybin, promote neural plasticity caused by a rapid and persistent growth of dendritic spines, which can facilitate the remodelling of neural circuits. Preclinical and clinical studies using psychedelic compounds have demonstrated efficacy for various neuropsychiatric disorders, which are often comorbid with obesity, and share underlying neural mechanisms. Here, we evaluate the effects of a single dose of psilocybin on body weight, food intake and energy expenditure in diet-induced obese (DIO) mice switched onto a low-fat chow. Psilocybin exacerbated diet-induced weight loss over a four-week period in DIO mice and increased the susceptibility for mice to exhibit more profound weight loss. Psilocybin appears to exert these effects predominantly through modulating food intake, with no influence on energy expenditure. No differences were observed in body weight or food intake in DIO mice maintained on a high-fat diet, indicating psilocybin does not necessarily directly promote weight loss or reduce food intake. Rather, it may help facilitate weight loss, provided it is administered in combination with other weight loss promoting interventions. Additional experimentation is required to examine the precise mechanisms involved; however, this data supports further investigation into the use of psychedelic compounds as an adjunct therapy for obesity.

Indexed as

Energy MetabolismHallucinogensObesityPsilocybinWeight LossAnimalsBody WeightDiet, High-FatEatingMaleMiceMice, Inbred C57BLMice, ObeseHallucinogensPsilocybin

Identifiers

PMID41980923
PMCPMC13187204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.